{
    "Trade/Device Name(s)": [
        "MammaPrint\u00ae"
    ],
    "Submitter Information": "Agendia BV",
    "510(k) Number": "K080252",
    "Predicate Device Reference 510(k) Number(s)": [
        "K070675"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NYI"
    ],
    "Summary Letter Date": "July 21, 2008",
    "Summary Letter Received Date": "May 9, 2008",
    "Submission Date": "May 7, 2008",
    "Regulation Number(s)": [
        "21 CFR 866.6040"
    ],
    "Regulation Name(s)": [
        "Gene expression profiling test system for breast cancer prognosis"
    ],
    "Analyte Class(es)": [
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Gene expression profile for breast cancer prognosis (70-gene signature)"
    ],
    "Specimen Type(s)": [
        "Fresh breast cancer tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "MammaPrint microarray",
        "Agilent DNA microarray scanner G2505B"
    ],
    "Method(s)/Technology(ies)": [
        "Microarray-based gene expression analysis"
    ],
    "Methodologies": [
        "Gene expression profiling"
    ],
    "Submission Type(s)": [
        "Test",
        "Service"
    ],
    "Document Summary": "FDA 510(k) summary for MammaPrint microarray-based gene expression profiling test to assess risk of distant metastasis in breast cancer patients.",
    "Indications for Use Summary": "Qualitative in vitro diagnostic test to assess risk for distant metastasis in breast cancer patients less than 61 years old, Stage I/II, tumor size \u22645.0 cm, lymph node negative, as a prognostic marker used with other clinicopathological factors.",
    "fda_folder": "Immunology"
}